‹ All Posts
MBA Investmentwala

1 hour ago · SEBI Registration INH000011185

Natco Pharma Receives US FDA Report for Vizag Unit

NATCOPHARM Natco Pharma Limited has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its Finished Dosage Formulations (FDF) manufacturing facility at Parawada, Visakhapatnam, Andhra Pradesh. The inspection has been classified as Voluntary Action Indicated (VAI). Key Regulatory Details Facility: Parawada, Visakhapatnam Inspection Period: August 17–21, 2026 Regulator: US FDA Form 483 Observations: 4 Final Classification: Voluntary Action Indicated (VAI) EIR Received: November 20, 2026 What Does VAI Mean? VAI indicates that the FDA identified objectionable conditions requiring voluntary corrective action. The observations do not currently warrant official regulatory enforcement action. It is different from an Official Action Indicated (OAI) classification, which may lead to regulatory action. Why It Matters: The Visakhapatnam facility manufactures finished dosage formulations. Regulatory compliance is important for supplying pharmaceutical products to the US market. Receipt of the EIR provides clarity on the outcome of the August inspection. Investor Perspective: The VAI classification is more favourable than an OAI outcome, but it should not be interpreted as a clean inspection with no observations. Investors should monitor corrective actions, future regulatory updates and the compliance status of Natco Pharma's manufacturing facilities. Disclaimer: This content is for educational and informational purposes only and should not be considered investment advice or a recommendation to buy or sell any security. Investors should conduct their own research and consider their risk profile before making any investment decision.

#WatchOutFor#StockInNews
7 likes·7 comments